Presenting SUPRA CAR T cells – a split, universal, and programmable CAR system

T cells expressing chimeric antigen receptors (CAR T) are particularly promising for the treatment of refractory cancers. While Kymriah and Yescarta are FDA-approved for B-cell malignancies, safety and efficacy concerns remain across the cell therapy industry. Severe cytokine release syndrome triggered by T cell infusion is one of the urgent CAR T related downsides that needs

Akron Biotech participates in the Phacilitate Automation Special Interest Group

Last week, Akron participated in the Phacilitate Automation Special Interest Group, a gathering of key industry stakeholders aimed at fostering discussion around the main challenges associated with developing and implementing automation solutions in an industry characterized by process variety and complexity, as well as the need to ensure data integrity. According to Dr. Rodney Rietze,

Interview with leading CAR T pioneer, Michel Sadelain, published in Human Gene Therapy

Michel Sadelain, MD, PhD, Director of the Center for Cell Engineering at Memorial Sloan-Kettering Cancer Center, recently sat down with Jennifer Adair, PhD, of the Fred Hutchinson Cancer Research Center to discuss the remarkable progress being made in the field of chimeric antigen receptor (CAR) engineered T-cell therapies to treat cancer. CAR T-cell therapies consist

Akron Biotech and U.S.-based industry leaders meet with the Argentine regulatory authority (ANMAT) to discuss regulatory developments in regenerative medicine

Last week, the Akron team joined more than 1,600 participants from 50+ countries at the annual meeting of the International Society for Cell and Gene Therapy (ISCT) in Montreal. Chaired by David DiGiusto, PhD (Stanford School of Medicine), Sarah Nikiforow, MD, PhD (Dana Farber Cancer Institute), and Denis-Claude Roy, MD, FRCPC (Hôpital Maisonneuve-Rosemont), the meeting

Join Akron at ISCT 2018

Riding the commercial approvals of two CAR T immunotherapies last year, the energized regenerative medicine community will be coming together in Montreal for the Annual ISCT Global Meeting and Exhibition from Wednesday May 2nd through Saturday May 5th. Don’t miss Dr. Claudia Zylberberg, CEO of Akron Biotech, during the Quality & Operations Track speaking about

Innate Killer Summit 2018 presents cutting-edge innovations and the latest clinical data for NK cell therapies

Akron Biotech was proud to be a sponsor of this year’s Innate Killer Summit held in San Diego, California. The Innate Killer Summit is the leading, dedicated end-to-end meeting serving as a catalyst to ensure successful clinical and commercial translation of NK cell immunotherapies. The most current and advanced clinical data was presented as well